Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.73 |
| ▸ | CA1 | P00915 | 4/20 | 0.73 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | CA9 | Q16790 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benznidazole SCHEMBL2324217 | 0.94 | CYP3A4 (0.89) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| Benznidazole SCHEMBL17560897 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL29663426 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| Benznidazole SCHEMBL2329527 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL15312866 | 0.85 | CA2 (1.00) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL15024639 | 0.81 | LMNA (0.80) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL11946680 | 0.79 | CYP3A4 (0.65) | CYP3A4CYP2D6OPRK1LMNAKMT2A | |
| Etanidazole SCHEMBL8171462 | 0.79 | LMNA (1.00) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| Etanidazole SCHEMBL4414 | 0.79 | LMNA (1.00) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL10247465 | 0.79 | CYP3A4 (0.65) | CYP3A4CYP2D6OPRK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4003 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250268934-A1 | Compositions and Methods for the Treatment of Bacterial Vaginosis | WAYNE STATE UNIVERSITY (US) | 2025-08-28 | — | — | US | claimed |
| US-20250222066-A1 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| US-12311054-B2 | Compositions and methods of using propylene sulfide-based polymers for treatment of Chagas disease | NORTHWESTERN UNIVERSITY (US) | 2025-05-27 | — | — | US | claimed |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4547023-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | University of Utah Research Foundation (US) | 2025-05-07 | — | — | EP | claimed |
| WO-2025085790-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VAGINITIS | WAYNE STATE UNIVERSITY (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20250059153-A1 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | IC-MedTech Corp. | 2025-02-20 | — | — | US | claimed |
| US-6271203-B1 | Anti-protozoan methods and materials | XOMA CORPORATION | 2001-08-07 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2000076316-A1 | METHODS RELATED TO METABOLISM OF PARASITES AND MYCOBACTERIA | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | claimed |
| EP-1052990-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2000-11-22 | — | — | EP | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-1999025347-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 1999-05-27 | — | — | WO | claimed |
| WO-1999012547-A1 | TREATMENT OF INFLAMMATORY CONDITIONS | THERAMARK LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
| WO-1999012548-A1 | TREATMENT OF INFLAMMATORY CONDITIONS | THERAMARK LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
| US-5646114-A | Anti-protozoan methods | XOMA CORPORATION (US) | 1997-07-08 | — | — | US | claimed |
| US-5273992-A | Administering one of a class of compounds of N-imidazole and N-nitroimidazole derivatives; inhibition of the calcium-activated potassium channels at the membranes | BETH ISRAEL HOSPITAL ASSOC. INC. (US) | 1993-12-28 | — | — | US | claimed |